Chamberlin L2-5 Flashcards

1
Q

What are the risk factors for atherosclerosis?

A
  • Genetics (NM)
  • Dyslipidaemia (M)
  • Diabetes (M)
  • Hypertension (M)
  • Obesity (M)
  • Smoking/alcohol (M)
  • Stress (M)
  • Physical activity (M)
  • Inflammation (NM)
  • Age (NM)
  • Family history (NM)
    NM = Non modifiable / M = Modifiable through drugs or lifestyle
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What are the characteristics of atherosclerosis?

A

The principal cause of heart attack (myocardial infarction MI), stroke and gangrene of the extremities. One of the major causes of death in Europe, USA & Japan. Main problem comes when plaque ruptures leading to thrombus formation and ultimately death. Influenced by a multitude of lifestyle choices, medical conditions & haemodynamics of blood flow itself. Can take years/decades to develop. Often remain symptomless for majority of life. Start of symptoms signals advanced disease. Always begins with an initial insult to the artery wall.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Where is atherosclerosis often found?

A

Found within peripheral and coronary arteries. Focal distribution along the artery length. Distribution may be governed by haemodynamic factors: Changes in flow/turbulence (eg at bifurcations) alter gene expression - areas prone to atherosclerosis.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

What is the structure of an atheroscletoric plague?

A
  • Lipid
  • Necrotic core
  • Connective tissue
  • Fibrous “cap”
    Eventually the plaque will either occlude the vessel lumen resulting in a restriction of blood flow (angina), or it may “rupture” (thrombus formation – death).
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

What was the response to injury hypothesis?

A

Suggested in 1856 by Rudolph Virchow and updated by Russell Ross in 1993 and 1999: Initiated by an injury to the endothelial cells which leads to endothelial dysfunction. Signals such as cytokines are sent to inflammatory cells which then accumulate and migrate into the vessel wall, leading to inflammation.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

What causes inflammation in arterial wall during atherosclerosis?

A

LDL - can pass in and out of the arterial wall in excess, accumulates in arterial wall. ECs and macrophages generate free radicals. LDL is oxidised by free radicals (oxLDL). oxLDL is engulfed by macrophages (via scavenger receptors) to form foam cells. Foam cells (macrophage full of lipids) release more pro-inflammatory cytokines, creating more and more foam cells in intima layer of arterial wall.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Why does LDL accumulate in specific regions of the arterial tree?

A
  1. Healthy endothelium produces NO (nitric oxide) and other mediators, protect against atheroma.
    a. Damaged endothelium alters NO biosynthesis
    b. Affects BP control, regional blood flow.
  2. Alteration in shear stress (frictional force blood exerts on vessel wall).
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

What is turbulent flow?

A

Arterial junctions or bifurcations experience lower levels of wall shear stress (WSS) compared to straight vessel segments. These areas of low shear stress experience turbulent flow, as opposed to laminar flow. Turbulent flow is more athero-prone due to a disruption of endothelial integrity and greater LDL-C infiltration.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

How is adhesion stimulated in atherosclerosis?

A

Endothelial cell (EC) activation prevents nitric oxide (NO) production due to increased oxidative stress. Causes the synthesis of adhesion molecules (ICAM-1, VCAM-1), chemokines (MCP-1) and pro-inflammatory cytokines (IL-1, TNF-α, and IL-6). The chemo-attractive gradient generated promote T-lymphocyte infiltration and a monocyte recruitment cascade involving capture, rolling, adhesion and eventual intimal transmigration.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

What causes plague rupture?

A

Plaques constantly growing and receding. Fibrous cap has to be resorbed and redeposited in order to be maintained. If balance shifted eg in favour of resorption, cap becomes weak and plaque ruptures. Results in basement membrane, collagen, and necrotic tissue exposure as well as haemorrhage of vessels within the plaque. End result: thrombus formation and vessel occlusion.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

What are the main causes of vulnerable plagues?

A
  • Necrotic core enlargement, a thinning of the fibrous cap and a heightened, uncontrolled inflammatory response.
  • Intimal ‘synthetic’ VSMCs express scavenger receptors that facilitate oxLDL uptake to form VSMC-derived foam cells, which secrete pro-inflammatory cytokines.
  • Specific cytokines (eg, IFN𝛾) inhibit collagen production in VSMCs, which causes a thinning of the fibrous cap due to impaired strength maintenance.
  • IFN𝛾 and other inflammatory mediators trigger increased pro-atherogenic cytokine release, MMP production, collagen degradation and greater plaque vulnerability.
  • As unresolved inflammation prevails, maintenance of a rigid fibrous cap is impaired and plaque susceptibility to rupture is increased.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

What occurs after plague rupture?

A

Rupture releases pro-thrombogenic factors that cause thrombosis when exposed to platelets and coagulating factors within the plasma. Cholesterol crystals play a fundamental role in inducing plaque rupture as they have been shown to perforate the fibrous cap. Clinical complications may arise as a result of coronary thrombosis caused by plaque rupture or erosion.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

What are fibrous plaques characterised by?

A

Characterised by less lipid accumulation, greater VSMC and ECM protein composition and fewer inflammatory macrophages are more prone to triggering thrombosis via plaque erosion. A complete absence of local ECs occurs in eroded plaques due to EC apoptosis, caused by innate immune activation and neutrophil extracellular traps (NETs). (Compared to ruptured plaques that possess dysfunctional ECs).

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

What is the long summary of athersclerosis?

A

Dysfunctional ECs and retention of LDL in subendothelial space. LDL is oxidised – promotes activation of ECs. Activated ECs increase expression of monocyte interaction/adhesion molecules (selectins, VCAM-1), and chemoattractants (MCP-1). Leads to attachment and migration of monocytes and T-lymphocytes into intima. Monocytes differentiate into macrophages.
Macrophages engulf ox-LDL via scavenger receptors (CD36, LOX-1) to become foam cells. Foam cells secrete IL-1 and other pro-inflammatory cytokines that generate another chemoattractive gradient and create a cycle of increased monocyte recruitment, higher foam cell production and greater inflammation, ultimately resulting in lesion growth. This is the start of formation of the fibrous cap.
Foam cells undergo apoptosis and release their lipid content to create isolated pools of cholesterol crystals within the intima. Pro-inflammatory cytokines, growth factors and matrix metalloproteinases (MMPs), secreted by activated foam cells and vascular ECs promote the migration of vascular smooth muscle cells (VSMCs) from the media to the intima. The macrophage-mediated clearance of apoptotic cells is inhibited.
This results in secondary necrosis of foam cells and the development of a necrotic core. VSMCs ‘phenotypic switching’ from a ‘contractile’ to ‘synthetic’ phenotype mediated by oxLDL and cholesterol crystals. ‘Synthetic’ VSMCs secrete extracellular matrix (ECM) proteins (collagen, proteoglycans and elastins) that contribute to the formation of stable plaque consisting of a fibrous cap overlying the necrotic core. The maintenance of a thick fibrous cap is critical for ensuring plaque stability. Anti-inflammatory cytokines (IL-10 and TGF-𝛽) secreted by T-lymphocytes reduce the size of the necrotic core by promoting effective removal of apoptotic cells. Anti-elastase activity of HDL reduce the size of the necrotic core by preventing fibrous cap ECM degradation. Advanced lesions impede blood flow and are prone to rupture.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

What is the process of atherosclerosis?

A
  1. Endothelial dysfunction causes adhesion molecules (ICAM-1 and VCAM-1) expression
    2-4: Monocytes are recruited, trans-migrate to the intima and differentiate into macrophages.
    5: Intimal LDL is oxidised to oxLDL, then engulfed by macrophages to form foam cells.
  2. Due to defective efferocytosis, foam cell necrosis occurs, resulting cholesterol-rich necrotic core formation.
  3. Growth factors and MMPs released from activated ECs and foam cells promote SMC migration into the intima where they adopt a ‘synthetic’ phenotype and can engulf oxLDL to become foam cells.
  4. The ‘synthetic VSMCs secrete ECM proteins that contribute to fibrous cap development overlying the necrotic core.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

How are lipids transported around the body?

A

Lipids are transported around the body as lipoproteins due to their hydrophobic nature. General structure is central core of hydrophobic lipid (triglycerides, cholesterol) surrounded by hydrophilic coat (phospholipids, free cholesterol, apolipoproteins.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

What are the different kinds of lipoproteins?

A

Lipoproteins can be HDL (smallest), LDL, VLDL and chylomicrons (largest). Classified due to density and the apolipoproteins that are associated. HDL (contain apoA1 and apoA2), diameter 7–20 nm. LDL (contain apoB-100), diameter 20–30 nm. Very-low-density lipoprotein (VLDL) (contain apoB-100), diameter 30–80 nm. Chylomicrons (contain apoB-48), diameter 100–1000 nm.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

What are the three pathways for lipid transport?

A
  1. Exogenous (dietary: gut to liver)
  2. Endogenous (liver to cells)
  3. Reverse cholesterol (cells to liver)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

What is the exogenous pathway of lipid transport?

A

Dietary lipid digested into cholesterol, free fatty acids and monoacylglycerides (MAG). FFA and MAG absorbed into enterocytes and used to form triglycerides, phospholipid and cholesterol ester. Cholesterol passes into enterocytes via NPC1L1. This transport protein is targeted by drugs affecting this pathway. Triglycerides and cholesterol packaged into chylomicron, containing ApoB48, via several steps in endoplasmic reticulum. Nascent (inactive) chylomicron released into lymphatic system.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

What is the metabolism of the exogenous pathway?

A

Lipids are digested. Chylomicrons are assembled with apolipoprotein B-48. Chylomicrons move into the liver and subsequently into the bloodstream, where HDL donates apolipoprotein C-II and E, forming a mature chylomicron. ApoC can only bind to receptors found on adipose tissue while ApoE can only bind to receptors on hepatocytes. Mature chylomicrons activate lipotein lipase (LPL), an enzyme found on the surface of cells. LPL catalyzes a hydrolysis reaction, releasing glycerol and fatty acids from the chylomicrons. Glycerol and fatty acids can be absorbed by the tissue. Remnants bind ApoE at the liver and are endocytosed and hydrolyzed within lysosomes. This also releases glycerol and fatty acids in the cell. Cholesterol & TG enter endogenous pathway, converted to bile, or excreted.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

What is the metabolism of the endogenous pathway of lipid transport?

A

In the liver, triacylglycerol and cholesterol are assembled with apolipoprotein B-100 to form VLDL. HDL donates apolipoprotein C-II and E. Apolipoprotein C-II activates LPL, causing hydrolysis of the VLDL particle and the release of glycerol and fatty acids. Glycerol and fatty acids can be absorbed by adipose tissue and muscle. The hydrolyzed VLDL particles are now called IDL. IDLs return to the liver and are further hydrolyzed by hepatic lipase. This releases glycerol and fatty acids, leaving behind IDL remnants, called LDL. After LDLs bind to target tissues, they are endocytosized. The internalized LDL particles are hydrolyzed with lysosomes, releasing mainly cholesterol.

22
Q

What is the metabolism of the reverse cholesterol pathway of lipid transport?

A

ApoA1 of HDL binds to transport proteins ABC-A1 or ABC-G1 in macrophages/foam cells and adsorbs cholesterol. HDL then transports cholesterol to liver via either:
- Indirect pathway: cholesterol esters transfer to VLDL, IDL or LDL particles via cholesterol ester transport protein (CETP). LDL/IDL/VLDL binds to LDLR on liver via ApoB100.
- Direct pathway: ApoA1 of HDL binds SRB1 receptor on liver. Cholesterol transferred to liver - Hepatic Lipase involved. HDL recirculates.
Cholesterol in liver processed and secreted in bile or transported to intestine via ABC-G5/G8 for excretion.

23
Q

What is dyslipidaemia?

A

An abnormal amount of lipids in the blood. Most dyslipidemias are hyperlipidemias: an elevation of lipids in the blood. May be primary or secondary to a disease.

24
Q

What are the two types of dyslipidaemia?

A

Primary and Secondary

25
Q

What is primary dyslipidaemia?

A

Due to a combination of diet and genetics. Usually polygenic (involve multiple genes). Can be monogenic (one gene). Classified according to which lipoprotein is abnormal. Type II: Familial Hypercholesterolaemia gives greatest risk and so is the one targeted therapeutically.

26
Q

What is secondary dyslipidaemia?

A

A consequence of other conditions e.g. diabetes, alcoholism, chronic renal failure, liver disease and administration of drugs (e.g. isotretinoin (treatment of severe acne), tamoxifen, cyclosporine and protease inhibitors used to treat HIV). Secondary forms are treated where possible by correcting the underlying cause.

27
Q

How is primary dyslipidaemia classified?

A

Classified according to which lipoprotein particle is abnormal. Six phenotypes, known as the Frederickson classification. The higher the LDL and the lower the HDL, the higher the risk of IHD.

28
Q

What are the characteristics of familiar hypercholesterolemia?

A

Genetic disorder causing very high levels LDL in the blood & early cardiovascular disease (CVD). Most FH have mutations in either 1) LDLR gene (encodes the LDL receptor protein, which removes LDL from the circulation). 2) Apolipoprotein B (ApoB), which is the part of LDL that binds with the receptor. Mutations in other genes are rare, but exist. Can be homozygous (rare) or heterozygous (1:500 people).
Heterozygous LDLR gene defect may have premature CVD at the age of 30 to 40. Homozygous LDLR gene defect may cause severe CVD in childhood.

29
Q

What is targeted in the treatment of atherosclerosis?

A

LDLs in particular trying to decrease them.

30
Q

What are the main drugs available for treatment of atherosclerosis?

A
  • Statins: 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors
  • Inhibitors of cholesterol absorption
  • PCSK9 inhibitor
31
Q

What is HMG-CoA reductase?

A

rate-limiting enzyme in cholesterol synthesis. Controls excessive cholesterol formation by a feedback mechanism

32
Q

How do statins work?

A

Statins regulate cholesterol levels by targeting HMG-CoA reductase. Target endogenous lipid transport pathway.

33
Q

Where are short acting statins absorbed?

A

Liver. Subject to extensive pre-systemic metabolism via Cyt P450 and glucuronidation pathways.

34
Q

What is statins mechanism?

A

Statins decrease cholesterol synthesis in the liver causing an increase in LDL receptor synthesis. Increased LDLR causes increased LDL clearance from plasma into the liver. Therefore: statins reduce plasma LDL. Also reduce plasma triglyceride and increase HDL.

35
Q

What occurs with products of mevalonate pathway?

A

Products of the mevalonate pathway are involved with lipidation. ie, react with protein to add a hydrophobic group. The fatty groups serve as anchors, to localise the proteins in organelles. Several important membrane-bound enzymes (e.g. endothelial NO synthase) are modified in this way. Therefore, by inhibiting mevalonate pathway, statins also affect lipidation.

36
Q

What can affecting lipidation do?

A
  • improved endothelial function
  • reduced vascular inflammation
  • reduced platelet aggregability
  • increased neovascularisation of ischaemic tissue
  • increased circulating endothelial progenitor cells
  • stabilisation of atherosclerotic plaque
  • antithrombotic actions
  • enhanced fibrinolysis
  • inhibition of germ cell migration during development
  • immune suppression
  • protection against sepsis
37
Q

What drug is an inhibitor of cholesterol absorption?

A

Ezetimibe (Zetia) = one of a group of azetidinone cholesterol absorption inhibitors

38
Q

What is the action of Ezetimibe?

A
  • Blocks intestinal absorption of cholesterol by blocking a transport protein (NPC1L1) in the brush border of enterocytes. Does not affect absorption of fat-soluble vitamins, triglycerides or bile acids. Has high potency – 10mg/day reduces LDL cholesterol by 17-19%. Targets exogenous lipid transport pathway. Generally given as an adjunct to diet plus statins.
39
Q

What drug is a PCSK9 inhibitor?

A

Repatha (evolocumab) = a human monoclonal antibody (IgG2) to Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)

40
Q

What lipid transport pathway does PCSK9 inhibitor target?

A

Endogenous and reverse cholesterol pathway.

41
Q

What is action of PCSK9?

A

PCSK9 binds LDLR. Complex internalizes, the receptor undergoes lysosomal degradation. LDL continues to circulate

42
Q

What is the mechanism of action for Evolocumab?

A
  • Evolocumab binds to PCSK9
  • Prevents circulating PCSK9 from binding to LDLR.
  • Prevents PCSK9-mediated LDLR degradation
  • LDL binds LDLR, internalises, LDL released
  • LDLR to recycles back to the liver cell surface.
  • Increases the number of LDLRs available to clear LDL from the blood
  • Lowers circulating LDL levels
43
Q

What is inclisiran?

A

chemically synthesized small interfering RNA designed to target PCSK9 messenger RNA. Long-acting, subcutaneously delivered, synthetic siRNA directed against PCSK9 that is conjugated to triantennary N-acetylgalactosamine carbohydrates.

44
Q

What is the role of N-acetylgalactosamine carbohydrates in terms of inclisiran action?

A

The carbs bind to abundant liver expressed asialoglycoprotein receptors, leading to inclisiran uptake specifically into hepatocytes.

45
Q

What does inclisiran do once uptaked by hepatocytes?

A

The siRNA molecules engage the natural pathway of RNA interference (RNAi) by binding intracellularly to the RNA-induced silencing complex (RISC), enabling it to cleave messenger RNA (mRNA) molecules encoding PCSK9 specifically. The cleaved mRNA is degraded and thus unavailable for protein translation, which results in decreased levels of the PCSK9 protein. A single siRNA-bound RISC is catalytic and cleaves many transcripts.

46
Q

Where are inhibitors of cholesterol absorption isolated from?

A

Isolated from wood pulp and used to make margarines or yoghurts. Stanol ester is hydrolyzed into stanols and fatty acids in digestive tract. Stanols & sterols are structurally similar to cholesterol - incorporated into mixed micelles replacing the cholesterol.

47
Q

What is the result of using inhibitors of cholesterol absorption?

A

Result = less cholesterol (40-45%) is absorbed into the bloodstream. Less absorption = reduced serum total and LDL cholesterol concentrations. May also activate transporter proteins (ABCG5/ABCG8 heterodimer) within enterocytes – increases movement of cholesterol from enterocytes back into the intestinal lumen to be excreted.

48
Q

How can you plant sterols be digested for optimal efficacy?

A

Plant stanols should to be taken as part of a meal. Plant stanols particles are virtually unabsorbed by the body – retain efficacy long-term.

49
Q

What new drugs are available for atherosclerosis treatment?

A

Bempedoic Acid: Clinical trials. Lowers LDL levels in conjunction with ezetemibe. Useful for patients that cannot tolerate statin?

50
Q

What is the action of Bempedoic acid?

A

Bempedoic acid is a prodrug. Inhibits ATP citrate lyase, which is involved in the liver’s biosynthesis of cholesterol upstream of HMG-CoA reductase.

51
Q

What are the two types of Bempedoic acid?

A
  1. Nilemdo - this is Bempedoic acid only
  2. Nustendi - combination of bempedoic acid and ezetimibe
52
Q

What are new anti-inflammatory agents?

A
  • Canakinumab (CANTOS trial)
  • IL-1b antibody